Trever G. Bivona, M.D., Ph.D. (standing) tells the Wall Street Journal how precision medicine is leading to gene breakthroughs and a revolution in the treatment of lung cancer, the goal - pairing a drug with the specific mutation fueling a patient’s disease. (Also pictured Bivona Lab research specialist Elton Chan).
In the two largest ever clinical studies on the molecular genetics of lung cancer, an international team, led by thoracic surgeons David M. Jablons, M.D. (left), Michael Mann, M.D., and Johannes Kratz, M.D., a former surgical resident, showed a molecular test better predicted death from early-stage lung cancer than conventional staging.
A molecular test developed by physician-scientists at UCSF may better predict post-operative mortality in early-stage lung cancer patients. Building on earlier work, the group identified a group of post-operative patients with the earliest stage of lung cancer who had a high likelihood of recurrence.
Lung cancer is the leading cause of cancer death worldwide and the Thoracic Oncology Program is poised to conquer it. UCSF provides state-of-the-art care to patients with lung cancer, mesothelioma, esophageal cancer, sarcoma and cancer that has metastasized to the chest. The program is led by David M. Jablons, M.D., Chief of the Section of General Thoracic Surgery and Program Leader of the Thoracic Oncology Program. Patients receive treatment from a dedicated multidisciplinary team of specialists. At UCSF, one of the world's leading biomedical research centers, patients also have access to clinical trials for promising new drugs.